Lifeworks Advisors LLC Has $6.52 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Lifeworks Advisors LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 4.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 257,377 shares of the biopharmaceutical company's stock after acquiring an additional 10,753 shares during the quarter. Pfizer accounts for 1.1% of Lifeworks Advisors LLC's holdings, making the stock its 24th largest holding. Lifeworks Advisors LLC's holdings in Pfizer were worth $6,522,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PFE. Norges Bank bought a new position in Pfizer in the fourth quarter valued at approximately $2,328,986,000. Starboard Value LP bought a new position in Pfizer in the fourth quarter valued at approximately $407,730,000. Assenagon Asset Management S.A. increased its stake in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. grew its stake in shares of Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after buying an additional 5,153,257 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. TD Cowen decreased their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Redburn Atlantic decreased their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. HSBC decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.55.

Pfizer Trading Up 0.1%

PFE stock traded up $0.01 during midday trading on Thursday, hitting $25.37. The stock had a trading volume of 25,643,723 shares, compared to its average volume of 38,513,248. The firm has a market cap of $144.25 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business has a fifty day moving average price of $24.26 and a two-hundred day moving average price of $24.70.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.78%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.